Bank of America Merrill Lynch Japan Conference 2016



The Growth Strategy of Shionogi

September 14, 2016

Isao Teshirogi, Ph.D. President and CEO



SHIONOGI's Growth Strategy toward 2020



Grow as a drug discovery-based pharmaceutical company

Top-line Growth

- Clear priorities and focused resourcing
 - Sales areas: Japan and US
 - Therapeutic areas: infectious disease and pain/CNS
- Approve and launch compounds in infectious diseases and pain/CNS areas

Bottom-line Growth


Continued improvement of business operations



S-0-N-0

for you

Growth by Leveraging the Strengths of Shionogi





Medium-term Business Plans since FY2000

S-O-N-G for you!

1st stage: Laying the foundation (FY2000 - 2004)

- Focused specifically on the prescription drug business
- Established infrastructure for global development

2nd stage: Accelerating toward significant strides (FY2005 - 2009)

- Focused R&D efforts on priority therapeutic areas (infectious diseases, pain, and metabolic syndrome)
- Acquired US-based Sciele Pharma, Inc.

3rd stage: SONG for the Real Growth (FY2010 - 2013)


- Established a new scheme for anti-HIV drugs
- Modified Crestor[®] royalty structure
- Launched Tivicay[®] and Osphena[®]

4th stage: Shionogi Growth Strategy "SGS2020" (FY2014 - 2020)

- Sales and therapeutic areas based on our strengths and the need of society (Sales area: Japan and the US, therapeutic area: infectious disease and pain/CNS)
- Three-year rolling plan to respond to rapid environmental changes



Continued Improvement of Business Operations






Aging societies worldwide

Economic pressure on healthcare systems

Increasing impact of drug-resistant bacteria and viruses Rising social needs for longer healthy life expectancy



Response to Rapid Environmental Changes



Three-year rolling plan: Reflect current results and business environment



S-O-N-G

for you!

Response to Rapid Environmental Changes

Experience in overcoming the Crestor® Cliff



Management skills with strong revenue base



SONG

Response to Rapid Environmental Changes

Revenue base

Royalty income (Crestor[®] and HIV franchise)



More compact (efficient)


- R&D activities
- Productivity



S-O-N-G

for vou!

Revenue Base: Expanding Royalty Income



- Growth of the HIV franchise covers the royalty income decrease in Crestor[®]
- Sales of the HIV franchise continue to increase strongly worldwide



SONG

for you!

History and Future Strategy of HIV Therapy

1996: Established ART using <u>three HIV medicines from at least two</u> <u>different drug classes</u>

• Converted HIV to a chronic disease, with patients surviving long-term with HIV

Development strategy of anti-HIV drugs: improvement in the precision of ART

- Development of new drugs with better safety, efficacy and resistance profile
- Combination drugs to improve the convenience for patients living with HIV

2013: Developed and launched dolutegravir (DTG)

- Good efficacy and safety
- Key drug with the potential to become LIC
- Expected good resistance profile demonstrated in post-launch experience

ViiV's strategy: New treatment regimens

- Two-drug single tablet regimens with DTG at the core therapy
- Development of cabotegravir LA

Competitors' strategy: Improve current regimens or withdraw from development


- Improvement of adverse effects
- Seeking new agents that could compete with DTG
- Withdrawal from HIV research, transfer HIV assets



5-0-N-G

HIV Integrase Inhibitor Franchise





ViiV's strategy to develop new treatment regimens to address the needs of people living with HIV places our HIV integrase inhibitors at the core of therapy




Sales Growth of Strategic Products in Japanese Market

Increase sales of strategic products by improving sales force impact


SONG for you!

- Transfer of marketing and manufacturing rights for twenty-four longlisted drugs
 - 3 products (oncology) \Rightarrow Nichiiko (July 2016)
 - 21 products (CNS etc.) ⇒ Kyowa Pharmaceutical (December 2016)



Rationale for the Transfer of 24 Long-listed Drugs

Business models depending on long-listed drugs is becoming more challenging due to the increasingly rapid penetration of generic drugs



Change in the generic drug ratio

Acceleration of generic drug use by the government

<NHI price revision in 2016>

- <u>Additional price cut</u> for long-listed drugs
- Lowering prices for the first generics (50% of the price of branded drugs)

Shionogi's Strategy: Continue to contribute to the advancement of healthcare and treatment by creating new drugs in infectious disease and pain/CNS areas



New Products to Drive Future Growth




Target milestone for launch of new product

FY2016	FY2017	FY2018				
Japanese business						
Crestor [®] OD tablet Cymbalta [®] Pain associated with chronic low back pain Pain associated with osteoarthritis ISODINE [®] brand ethical products	Naldemedine Guanfacine hydrochloride Oxycodone Tamper resistant formulation Moderate to severe chronic pain	S-033188 Lisdexamfetamine Actair [®] Pediatric patients with perennial allergic rhinitis				
US business						
	Naldemedine S-649266 Lusutrombopag	Osphena [®] Further indication: vaginal dryness associated with postmenopausal VVA				
Global out-licensed products						
		Dolutegravir + rilpivirine				



Commitment to Drug Discovery



Leveraging our capabilities in small molecule drug discovery
Open innovation: Identify novel drug seeds and develop them

SHIONOGI

S-0-N-0

for you!

S-033188 (Drug Candidate for Influenza Virus Infection)

S-033188				
Indication	Influenza virus infection			
Mechanism of action	Cap-dependent endonuclease inhibition (Novel mechanism of action)			
Special characteristics	Broad and potent antiviral activity against seasonal influenza A and B viruses as well as highly pathogenic avian influenza virus Single oral dose treatment			
Stage	Japan: Phase II Completion, US: Phase I			
Plan	Japan: Phase III, Global: Phase III: FY2016 Planned NDA submission in Japan: FY2017			
Notes	Designated for "Priority review system" by the MHLW Out-licensed to Roche except for Japan and Taiwan			





 Modified contracts with alliance partners to produce win-win outcomes

Naldemedine

 Exploring partnering options to maximize the value of naldemedine

BACE inhibitor

• Research collaboration with Janssen



5-0-N-(

for vou!

Global perspective

 Experience and expertise from Tamiflu[®] (Development, Supply, Commercialization)

Development rights by Shionogi


 Shionogi retains the rights to develop S-033188 under the "priority review system" in Japan



• Strengthening capability and experience in development in our prioritized therapeutic areas



S-033188: Non-Clinical & Phase I (Single Dose) Study




Single dose (6 mg) administration achieved plasma exposures that are expected result in efficacy surpassing currently marketed drugs



S-O-N-G






Pipeline (as of Aug. 2016)

Pain/CNS

Frontier





Pipeline (as of Aug. 2016)



Non-clinical	Phase I	Phase II	Phase III	NDA submission
[Out-licensed	3]	Cabotegravir + rilpivirine LAP Treatment for HIV infection		
GSK3342830 Multidrug-resistant Gram- negative bacterial infections		Cabotegravir LAP Prevention for HIV infection	Dolutegravir + rilpivirine Treatment for HIV infection	
Janssen/Shionogi Project compound Alzheimer's disease			Janssen/Shionogi BACE inhibitor Alzheimer's disease	






Balancing Shareholder Return and Investment for Our Future



Maximize enterprise value by balancing three key factors





Forward-Looking Statements

- S-O-N-G for you!
- Forecast or target figures in this material are neither official forecasts of earnings and dividends nor guarantee of target, achievement and forecasts, but present the midterm strategies, goals and visions. Official earnings guidance should be referred to in the disclosure of the annual financial report (*kessan tanshin*) in accordance with the rules set by Tokyo Stock Exchange.
- Materials and information provided during this presentation may contain so-called "forward-looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency's examination period, obtaining regulatory approvals; domestic and foreign healthcare reforms; trend toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- For products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
- Shionogi disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
- This material is presented to inform stakeholders of the views of Shionogi's management but should not be relied on solely in making investment and other decisions.
- You should rely on your own independent examination of us before investing in any securities issued by our company. Shionogi shall accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding or changes of target figures or any other use of this material.
- This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.

